Results on the IMMray™ PanCan-d optimization study to be presented at PancreasFest 2019
The results showed ROC AUC-values of 0.97, 0.98 and 0.96 differentiating pancreatic cancer (PDAC) vs. non-PDAC but symptomatic individuals, healthy controls and type II diabetes, respectively. Data for non-PDAC symptomatic patients, as well as diabetic patients, are novel and not reported before in literature.LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) today announced that, following the breakthrough news that was announced in June (link to PR ), the additional, more detailed data of the optimization study will be presented at